Treatment before mosunetuzumab
| Therapy . | n (% or range), N = 30 . |
|---|---|
| Lymphodepleting chemotherapy | 20 (67) |
| Fludarabine/cyclophosphamide | 18 (90) |
| Bendamustine | 2 (10) |
| Unknown | 10 (33) |
| Commercial anti-CD19 CAR-T | 4 (40) |
| Investigational CAR-T | 6 (60) |
| CAR-T product | |
| Commercial | 20 (67) |
| Axicabtagene ciloleucel | 10 (33) |
| Tisagenlecleucel | 7 (23) |
| Lisocabtagene maraleucel | 3 (10) |
| Investigational | 8 (27) |
| Anti-CD19 CAR-T | 6 (20) |
| Anti-CD20 CAR-T | 2 (7) |
| Unknown anti-CD19 CAR-T | 2 (7) |
| Bendamustine | 11 (37) |
| Within 6 months of mosunetuzumab | 1 (3) |
| Within 9 months of mosunetuzumab | 2 (7) |
| Within 12 months of mosunetuzumab | 4 (13) |
| Therapy administered between CAR-T infusion and mosunetuzumab | |
| No intervening therapy | 20 (67) |
| Median number of therapies received | 0 (0-1) |
| Investigational drugs, not otherwise specified | 3 (10) |
| Lenalidomide-rituximab | 2 (7) |
| Lenalidomide | 1 (3) |
| Ibrutinib | 1 (3) |
| Pembrolizumab | 1 (3) |
| Copanlisib | 1 (3) |
| R-ICE | 1 (3) |
| Therapy . | n (% or range), N = 30 . |
|---|---|
| Lymphodepleting chemotherapy | 20 (67) |
| Fludarabine/cyclophosphamide | 18 (90) |
| Bendamustine | 2 (10) |
| Unknown | 10 (33) |
| Commercial anti-CD19 CAR-T | 4 (40) |
| Investigational CAR-T | 6 (60) |
| CAR-T product | |
| Commercial | 20 (67) |
| Axicabtagene ciloleucel | 10 (33) |
| Tisagenlecleucel | 7 (23) |
| Lisocabtagene maraleucel | 3 (10) |
| Investigational | 8 (27) |
| Anti-CD19 CAR-T | 6 (20) |
| Anti-CD20 CAR-T | 2 (7) |
| Unknown anti-CD19 CAR-T | 2 (7) |
| Bendamustine | 11 (37) |
| Within 6 months of mosunetuzumab | 1 (3) |
| Within 9 months of mosunetuzumab | 2 (7) |
| Within 12 months of mosunetuzumab | 4 (13) |
| Therapy administered between CAR-T infusion and mosunetuzumab | |
| No intervening therapy | 20 (67) |
| Median number of therapies received | 0 (0-1) |
| Investigational drugs, not otherwise specified | 3 (10) |
| Lenalidomide-rituximab | 2 (7) |
| Lenalidomide | 1 (3) |
| Ibrutinib | 1 (3) |
| Pembrolizumab | 1 (3) |
| Copanlisib | 1 (3) |
| R-ICE | 1 (3) |
CAR, chimeric antigen receptor–modified; CAR-T, chimeric antigen receptor-modified T-cells; R-ICE, rituximab, ifosfamide, carboplatin, etoposide.